News

Zoetis Establishes Research Lab At CSU To Explore Immunotherapies For Livestock

Tuesday, July 30, 2019

Zoetis, the world’s leading animal health company, has signed an agreement with Colorado State University to establish a research lab at CSU that will explore the livestock immune system and target new immunotherapies – paving the way for new alternatives to antibiotics in food-producing animals. The new 3,000-square-foot Zoetis Incubator Research Lab will operate at the Research Innovation Center on CSU’s Foothills Campus starting in early 2020.

Read the full story at the Colorado State University's Source.

 
Continue Reading

Weekly Policy Update: Senate Finance Committee Advances Drug Pricing Package

Friday, July 26, 2019

On Thursday, the Senate Finance Committee advanced a major legislative package that includes substantial changes to Medicare and Medicaid drug reimbursement. The bill, the Prescription Drug Pricing Reduction Act, passed the Committee by a vote of 19-9 and will be considered by the full Senate in the fall. 

Agilent Announces Purchase of Boulder Facility

Thursday, July 25, 2019

Agilent Technologies has announced it is purchasing the building in Boulder where they have been manufacturing therapeutic oligonucleotides (“oligos") for over a decade. This $12 million purchase, along with their recent $150 million investment in their second oligo manufacturing site in Frederick, Colorado, more than doubles their capacity to produce oligos and reaffirms Agilent’s confidence in the therapeutic oligo market. Furthermore, it solidifies their commitment to doing business in the state of Colorado and their commitment to be a good corporate citizen in local communities.  

2019 Rocky Mountain Life Science Investor and Partnering Conference Announces Presenting Companies

Wednesday, July 24, 2019

September conference led by Colorado BioScience Association to provide companies from across the region new opportunities for capital access 
Continue Reading

Weekly Policy Update: We Work For Health Summit—CBSA Urges Federal Lawmakers to Promote Medical Innovation and Protect Patient Access

Monday, July 22, 2019

 

Viewray to Expand to Denver, Adding 274 Jobs

Tuesday, July 16, 2019

Viewray, Inc., an Ohio-based medical technology company that provides high-level MRI-guided radiation technology is expanding its operations in the metro Denver area and will be hiring 274 people over the next eight years.

Read the full story on the Denver Business Journal’s website.

 
Continue Reading

Weekly Policy Update: Trump Administration Pulls Rebate Rule

Monday, July 15, 2019

Last week the Trump Administration withdrew their proposed rebate rule that would have required manufacturer rebates to be passed through to patients in Part D and other government programs.  

Silvergate Pharmaceuticals Merges With CutisPharma To Serve Patients On Opposite Ends of the Spectrum

Wednesday, July 10, 2019

Silvergate Pharmaceuticals produces pediatric medications, while CutisPharma has served the senior population. They’re bringing their companies together to form Azurity Pharmaceuticals.

While it might initially seem like the two patient groups have little in common, Azurity’s CEO Neal Muni believes joining forces was a very natural move. Both populations often require specialized dosing and may struggle with swallowing pills.

“It made a lot of sense strategically to better serve our patients,” Muni said. “We started talking with Silvergate and their investors quite some time back about the potential opportunity to combine the two companies. With this combination of the two we can reaffirm our commitment to the same patient populations with much larger capability.”

Read the full article on the Denver Business Journal’s website.

 
Continue Reading

Cerapedics Announces Expansion of Colorado Headquarters

Monday, July 08, 2019

WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from 16 to 44 employees in Colorado and is increasing its facility from 14,000 to 24,000 square feet to accommodate further expansion through the end of 2019. In addition, Cerapedics is expanding its global workforce from 32 to 73 employees worldwide.

"We are excited to grow our Colorado footprint and bring more jobs and career opportunities to the Denver area," said Glen Kashuba, Chief Executive Officer of Cerapedics. "This expansion allows us to further control our value chain by relocating our distribution activities to our corporate headquarters. We now have the potential to double our headcount across key administrative, operational and sales support departments to meet the growing demand for i-FACTOR™ Peptide Enhanced Bone Graft and drive the business for years to come."

Cerapedics commercialized i‑FACTOR beginning in 2016 and has since increased its market space with continued growth of greater than 50% expected in 2019. i-FACTOR is a drug-device combination that accelerates new bone formation in patients with degenerative disc disease. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. Food & Drug Administration (FDA).

To further grow its product portfolio and support the company's commitment to enhancing the science of bone repair, Cerapedics is currently enrolling patients in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.

"We are excited about our future product offering and further advancement of our growing bone graft franchise," said Edward Sawyer, General Manager and Head of Colorado Operations for Cerapedics. "Expanding our facility enables us to double our Colorado staff to best service our customers and our product. We've benefited greatly from our Coloradolocation and are pleased to continue to expand our team of talented professionals. We have found a strong pool of talent upon which to utilize in the Denver Metro Area."

About Cerapedics

Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

CAUTION: P-15L Bone Graft is an Investigational Product limited by Federal (USA) Law to Investigational Use.

Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

 
Continue Reading

Weekly Policy Update: Drug Pricing Bills Pass Key Senate Committees

Monday, July 08, 2019